Mark William Lowdell is CSO at Inmune Bio, Inc. (INMB). They have made 3 open-market trades across 1 company since 2019, most recently 2026-07-02.
CIK 0001767037
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
2 open-market purchases totalling $138K since 2019, against 1 sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| INMB | 1,518,017 | $2.4M |
Shares reported on the most recent Form 4, priced at the 2026-07-07 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| INMB | BUY | 2024-04-19 | 2024-04-24 | $8.32 | $120K | +10.1% | -0.6% | -16.8% |
| INMB | SELL · 10b5-1 | 2021-11-03 | 2021-11-04 | $20.00 | $14K | -21.7% | -36.2% | -44.9% |
| INMB | SELL · 10b5-1 | 2021-10-27 | 2021-10-29 | $20.00 | $47K | -22.7% | -33.4% | -55.9% |
| INMB | SELL · 10b5-1 | 2021-10-22 | 2021-10-26 | $20.00 | $8K | -25.4% | -30.3% | -53.7% |
| INMB | SELL | 2021-07-07 | 2021-07-09 | $20.17 | $1.1M | -1.4% | -31.8% | -21.6% |
| INMB | BUY | 2019-09-11 | 2019-09-12 | $6.23 | $18K | -10.8% | -38.3% | -25.6% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.